Browse the evidence

Macrophage-secreted factors induce a profibrotic phenotype in human preadipocytes, characterized by increased proliferation, migration, and synthesis of extracellular matrix (ECM) proteins like fibronectin and collagen I.

Chronic obesity creates an inflammatory environment in fat tissue where immune cells signal fat precursor cells to become fibrotic and proliferative. This biological change makes fat tissue more resistant to change. Addressing obesity may require strategies that reduce inflammation, not just caloric restriction.

Inhibin A, secreted by macrophages or induced in preadipocytes, is a major profibrotic factor driving the synthesis of fibronectin and collagen I.

Inhibin A is identified as a specific protein that drives fat tissue scarring. This highlights a potential target for future therapies to reverse obesity-related fibrosis.

The fibronectin/integrin alpha5 partnership is essential for the proliferation of inflammatory preadipocytes.

Blocking the interaction between fibronectin and integrin alpha5 can stop the proliferation of fat precursor cells in a fibrotic environment.

NF-kappaB and Cyclin D1 are critical molecular links connecting inflammation, ECM remodeling, and preadipocyte proliferation.

Targeting NF-kappaB or Cyclin D1 pathways could potentially disrupt the cycle of inflammation and fibrosis in fat tissue.

Obesity induces a chronic low-grade inflammatory state characterized by macrophage infiltration and elevated proinflammatory cytokines (TNF-α, IL-6, IL-1β), which promotes cancer development through NF-κB activation and growth factor signaling.

Maintaining a healthy weight helps reduce chronic inflammation, which is a known biological driver of cancer risk. While weight management is complex, reducing excess adipose tissue can lower the levels of proinflammatory cytokines and hormones that promote tumor growth.

Adiponectin levels are inversely correlated with adiposity and exert anticancer effects by decreasing insulin/IGF-1 signaling and reducing proinflammatory cytokine expression.

Higher levels of adiponectin, which are typically found in leaner individuals, are associated with lower cancer risk. This hormone helps regulate glucose metabolism and reduces inflammation.

High luminal glucose concentrations trigger the translocation of the facilitative transporter GLUT2 to the brush border membrane (BBM) of enterocytes, thereby increasing the capacity for D-glucose absorption.

Your small intestine is designed to absorb glucose more efficiently when you consume a high-glucose meal. It does this by moving specific transporters (GLUT2) to the surface of the cells facing the gut lumen. This is a normal, healthy physiological response to maximize nutrient uptake from carbohydrate-rich foods.

SGLT1 abundance in the brush border membrane increases in response to high luminal glucose, mediating high-capacity glucose absorption.

When you eat foods high in glucose, your body increases the number of SGLT1 transporters on the surface of your intestinal cells. This allows your body to absorb more glucose efficiently from your meal.

GLUT5 is the primary facilitative transporter responsible for D-fructose absorption in the small intestine.

Your body uses a specific transporter called GLUT5 to absorb fructose (fruit sugar) from your small intestine. This is a dedicated pathway distinct from the primary glucose absorption mechanisms.

In older adults, age-related sarcopenia is mechanistically driven by increased SOCS-3 and myostatin levels, which inhibit Akt phosphorylation efficiency, leading to reduced muscle protein synthesis and fiber atrophy.

As you age, your body naturally increases signals (SOCS-3 and myostatin) that block muscle growth pathways. To combat this, you must actively stimulate muscle protein synthesis through resistance training and adequate protein intake to override these inhibitory signals, as passive aging leads to significant muscle fiber shrinkage.

In humans, changes in plasma leptin concentrations resulting from weight loss or gain do not correlate with changes in energy expenditure, suggesting leptin is not the primary signal mediating metabolic adaptation to altered body weight.

Your body's metabolic slowdown during weight loss is not primarily driven by leptin levels. While leptin does drop when you lose fat, this drop doesn't predict how much your metabolism will slow down. Focusing on leptin as the 'cause' of metabolic adaptation is likely a distraction from other physiological mechanisms.

Roux-en-Y gastric bypass (RYGB) increases postprandial GLP-1 and decreases TSH, whereas Laparoscopic Adjustable Gastric Banding (LAGB) does not, despite both causing similar weight loss.

RYGB surgery changes your gut hormone (GLP-1) and thyroid hormone (TSH) levels more than LAGB does, even if you lose the same amount of weight. This suggests the surgery itself, not just the weight loss, affects how your body regulates energy and appetite.

Skeletal muscle-derived myokines (Irisin, Cathepsin B) and metabolites (Lactate, β-Hydroxybutyrate, Kynurenic Acid) mediate exercise-induced neuroprotection, angiogenesis, and memory enhancement via blood-brain barrier signaling.

Regular physical activity sends chemical signals from your muscles to your brain that protect neurons, improve memory, and boost mood. You don't need to know the specific molecules; consistent exercise is the key to activating this muscle-to-brain communication system.

Exercise-induced elevation of muscle PGC-1α shifts kynurenine metabolism toward kynurenic acid, reducing neurotoxic kynurenine accumulation and conferring resistance to stress-induced depression.

For those struggling with stress or depression, regular endurance exercise helps your muscles process tryptophan in a way that prevents neurotoxic buildup in the brain. This biological mechanism offers protection against stress-induced mood disorders.

Skeletal muscle BMAL1 regulates sleep homeostasis and NREM sleep duration, demonstrating that peripheral tissue clocks influence central sleep processes.

Regular exercise helps synchronize your body's internal clocks, including those in your muscles, which in turn helps regulate your sleep duration and recovery. Consistent physical activity supports better sleep architecture.

Fibroblast Growth Factor 21 (FGF21) analogues improve plasma lipid profiles in humans but lack glucose-lowering efficacy in type-2 diabetic patients, contrasting with robust glucose and lipid improvements observed in mouse models.

If you are considering FGF21-based therapies for diabetes, understand that current evidence suggests they may help with blood fats (lipids) but are not expected to lower blood sugar levels in humans, unlike what was seen in laboratory mice. This highlights the importance of human-specific clinical data over animal studies.

Elevated circulating FGF21 levels in humans are associated with obesity, insulin resistance, and metabolic syndrome, suggesting a state of 'FGF21 resistance' similar to insulin resistance.

In obesity, your body produces high levels of FGF21 as a stress response, but you may become resistant to its effects. This resistance is linked to insulin resistance and metabolic syndrome. Managing weight and metabolic health may help restore sensitivity to this hormone.

Intrahepatic triglyceride content is the most proximate correlate of insulin resistance, independent of subcutaneous fat mass or overall obesity.

Focus on reducing liver fat rather than just total body weight. This can be achieved through weight loss (even moderate, ~8% loss reduces liver fat by ~50%) and by choosing a lower-fat diet compared to a high-fat diet. Monitoring liver health is crucial for metabolic risk, regardless of BMI.

A fatty liver actively overproduces cardiovascular risk factors, including VLDL, glucose, CRP, and coagulation factors, thereby increasing the risk of type 2 diabetes and cardiovascular disease.

Treating fatty liver is not just about liver health; it is a primary strategy for preventing heart disease and diabetes. Reducing liver fat through lifestyle changes or medication lowers the production of harmful substances like VLDL and inflammatory markers.

Perivascular adipose tissue (PVAT) dysfunction, characterized by reduced adiponectin secretion and increased pro-inflammatory cytokines, directly contributes to hypertension and insulin resistance by losing its anti-contractile effect on blood vessels.

Focus on reducing visceral fat rather than just total body weight. Strategies that promote 'beiging' of adipose tissue (like cold exposure) or reduce inflammation may help improve vascular health and blood pressure, even if overall weight loss is modest. Prioritize metabolic health markers over BMI.

Low circulating adiponectin levels are independently associated with the severity of liver histology (steatosis, necroinflammation, and fibrosis) in non-obese, non-diabetic patients with NASH, and this hypoadiponectinemia predicts impaired postprandial lipid metabolism.

For individuals with NASH, especially those who are not obese, maintaining higher levels of adiponectin is crucial for liver health. This can be supported by a diet higher in polyunsaturated fatty acids (PUFA) and lower in saturated fats, as PUFA intake was found to independently predict higher fasting adiponectin levels. Focus on dietary fat quality rather than just total fat or calories.

Impaired postprandial lipid metabolism, characterized by higher triglyceride and free fatty acid responses to an oral fat load, is linked to hypoadiponectinemia and independently predicts the severity of hepatic steatosis in NASH patients.

For NASH patients, the type and amount of fat consumed in a single meal can significantly impact liver fat accumulation. Since postprandial free fatty acids independently predict steatosis severity, managing post-meal lipid spikes through dietary fat quality (higher PUFA, lower SFA) is a practical strategy to support liver health.

Lactobacillus reuteri DSM 17938 supplementation does not significantly improve glycemic control (HbA1c) or insulin sensitivity in the general population of patients with type 2 diabetes on insulin therapy, although it may improve insulin sensitivity in a specific subgroup with high baseline gut microbiota diversity.

Taking Lactobacillus reuteri DSM 17938 (10^8 to 10^10 CFU daily for 12 weeks) will not lower your HbA1c or improve insulin sensitivity if you have type 2 diabetes, unless you already have a highly diverse gut microbiome. For most patients, this probiotic offers no metabolic advantage over a placebo.

Spaceflight induces significant sleep loss (~6.5 hours/night vs. scheduled 8 hours), reduced slow-wave sleep, and circadian misalignment due to non-24-hour light-dark cycles and low illuminance, leading to neurobehavioral performance decrements.

In high-stress, irregular environments, scheduled sleep time does not equal actual sleep time. Prioritize sleep environment (darkness, quiet) and consistency. If you are in a role requiring high cognitive performance, recognize that 'getting by' on less sleep leads to measurable performance deficits, even if you feel adapted.